<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2438">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129423</url>
  </required_header>
  <id_info>
    <org_study_id>GA43512</org_study_id>
    <nct_id>NCT05129423</nct_id>
  </id_info>
  <brief_title>A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot and dose-ranging study will evaluate the efficacy, safety, and pharmacokinetics of&#xD;
      MTPS9579A compared with placebo in participants with chronic spontaneous urticaria (CSU)&#xD;
      refractory to antihistamines. This study comprises two parts. In Part 1, participants will be&#xD;
      randomized to receive MTPS9579A or placebo. On the basis of positive results from Part 1, a&#xD;
      dose-ranging Part 2 may be opened, where participants will be randomized to receive one of&#xD;
      four MTPS9579A doses or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the UAS7</measure>
    <time_frame>Week 12</time_frame>
    <description>Change from baseline in the Urticaria Activity Score summed over 7 days (UAS7) at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Well-Controlled Urticaria</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants with well-controlled urticaria (UAS7&lt;=6) at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Complete Response</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants who achieve complete response (UAS7=0) at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 96 weeks</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of MTPS9579A</measure>
    <time_frame>Through Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Anti-Drug Antibodies (ADAs)</measure>
    <time_frame>Through Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADAs</measure>
    <time_frame>Through Week 20</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Spontaneous Urticaria</condition>
  <arm_group>
    <arm_group_label>Part 1: MTPS9579A Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, participants will receive MTPS9579A dose A every 4 weeks from randomization to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 1, participants will receive placebo matched with MTPS9579A, every 4 weeks from randomization through Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MTPS9579A Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, participants will receive MTPS9579A dose A, every 4 weeks from randomization to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MTPS9579A Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, participants will receive MTPS9579A dose B, every 4 weeks from randomization to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MTPS9579A Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, participants will receive MTPS9579A dose C, every 4 weeks from randomization to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MTPS9579A Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, participants will receive MTPS9579A dose D, every 4 weeks from randomization to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo Dose A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 2, participants will receive placebo matched with MTPS9579A dose A and B, every 4 weeks from randomization through Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo Dose B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 2, participants will receive placebo matched with MTPS9579A dose C and D, every 4 weeks from randomization through Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTPS9579A</intervention_name>
    <description>MTPS9579A will be administered.</description>
    <arm_group_label>Part 1: MTPS9579A Dose A</arm_group_label>
    <arm_group_label>Part 2: MTPS9579A Dose A</arm_group_label>
    <arm_group_label>Part 2: MTPS9579A Dose B</arm_group_label>
    <arm_group_label>Part 2: MTPS9579A Dose C</arm_group_label>
    <arm_group_label>Part 2: MTPS9579A Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched with MTPS9579A will be administered.</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo Dose A</arm_group_label>
    <arm_group_label>Part 2: Placebo Dose B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CSU refractory to sgH1-AHs at the time of randomization&#xD;
&#xD;
          -  Demonstrated ability to comply with the required use of the eDiary for the duration of&#xD;
             the study&#xD;
&#xD;
          -  For patients on H2 antihistamines or LTRAs for non-CSU indications, treatment at a&#xD;
             stable dose for &gt;=2 weeks prior to screening, with no anticipated changes throughout&#xD;
             duration of study, including the screening period&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent or use&#xD;
             contraception&#xD;
&#xD;
          -  For men: agreement to remain abstinent or use a condom, and agreement to refrain from&#xD;
             donating sperm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in a clinical trial of MTPS9579A&#xD;
&#xD;
          -  Chronic urticaria with known cause or other disease with symptoms of urticaria or&#xD;
             angioedema&#xD;
&#xD;
          -  Other skin disease associated with chronic itching&#xD;
&#xD;
          -  Uncontrolled disease where flares are commonly treated with systemic corticosteroids&#xD;
&#xD;
          -  History or evidence of any clinically significant medical condition/disease or&#xD;
             abnormalities in laboratory tests that, in the investigator's judgment, preclude the&#xD;
             patient's safe participation and completion of the study, or interferes with the&#xD;
             conduct and interpretation of the study&#xD;
&#xD;
          -  History of anaphylaxis without clearly identifiable avoidable antigen&#xD;
&#xD;
          -  History of anaphylaxis to any biologic therapy for any indication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GA43512 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

